.png "Jazz Pharmaceuticals (NASDAQ: JAZZ)")
H.C. Wainwright analyst Oren Livnat maintained a Hold rating on Jazz Pharmaceuticals (JAZZ) today and set a price target of $147. The company’s shares closed yesterday at $136.68.
Livnat said:
“Our $147 12-month target (from $153) is based on a DCF, which reflects a strong 15% 2019-22 cash- flow CAGR, a 10% WACC discount rate, and negative 3.5% terminal growth after 2022 given conservatively assumed modest Xyrem franchise headwinds partially offset by other products’ continued growth.”
According to TipRanks.com, Livnat is a 4-star analyst with an average return of 6.2% and a 49.6% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals Inc, Taiwan Liposome Company Ltd, and Collegium Pharmaceutical.
Currently, the analyst consensus on Jazz Pharmaceuticals is a Strong Buy with an average price target of $178.25, a 30.4% upside from current levels. In a report issued on July 26, Mizuho Securities also reiterated a Hold rating on the stock with a $154 price target.
See today’s analyst top recommended stocks >>
Jazz Pharmaceuticals’ market cap is currently $7.74B and has a P/E ratio of 17.04. The company has a Price to Book ratio of 2.85.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.
